NCT01869114 - Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 8, 2013

Primary Completion Date

April 19, 2028

Study Completion Date

April 19, 2028

Conditions

Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)de Novo Myelodysplastic SyndromesMyelodysplastic Syndrome With Isolated Del(5q)Previously Treated Myelodysplastic SyndromesRecurrent Adult Acute Myeloid Leukemia

Interventions

DRUG

Sirolimus

Given PO

DRUG

Azacitidine

Given IV

Trial Locations (5)

19001

Abington Hospital - Jefferson Health, Abington

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

19124

Jefferson Health, Aria Hospital, Philadelphia

19148

Jefferson Health, Methodist Hospital, Philadelphia

08012

Jefferson Health NJ Division (Kennedy Hospital), Sewell

All Listed Sponsors

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER